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32 Oral Presentationsmimic the role of filgrastim (F), resulting in at least an equivalent
shortening of post-PBSCT neutropenia.
NHL patients over the age of 18 years who were deemed eligible
for PBSCTwere identified prior to the administration of high-dose
chemotherapy, and following adequate harvest and cryopreserva-
tion of peripheral blood progenitor cells (ie, . 2.5  106 CD341
cells/kg). Eligible patients with preserved end organ function re-
ceived either standard BEAM or BEAC high-dose chemotherapy.
Prior to high-dose therapy, patients were randomly assigned to re-
ceive either P at a fixed-dose of 6 mg onDay11(Arm A), or weight-
based, dose-adjusted F rounded to the nearest prefilled syringe be-
ginning on Day 11(Arm B) following transplantation.
One-hundred one eligible patients were enrolled within US On-
cology Transplant Network between July 2003 and April 2007.
Three patients were deemed ineligible (CHF death, consent with-
drawn, other). The analyses and results presented below outline
the remaining 98. The demographic characteristics of both arms
were well-balanced with regards to stage at diagnosis and treatment,
ECOG Performance Status, histology, and lines of prior therapy.
The comparison of P vs F is summarized in the table that follows.
Transplant-related mortality and the incidence of Grade 3–4 ad-
verse events were comparable in both arms.
In conclusion, administration of pegfilgrastim post-PBSCT ap-
pears to be equivalent to multiple daily doses of filgrastim. Such
an approach might be considered in lieu of filgrastim thereby obvi-
ating the need for multiple daily injections.
Comparison of Pegfilgrastim (P) versus Filgrastim (F)
Arm A Arm B
Variable (Pegfilgrastim) (Filgrastim)No. of Patients Treated (n) 50 48
Doses Received (mean ± SD) 1.0 ± 0 12.7 ± 2.6
ANC Recovery (days) (mean ± SD) 8.3 ± 1.1 8.9 ± 1.5
RBC Transfusions (mean ± SD) 1.7 ± 0.9 1.9 ± 1.2
Platelet Transfusions (mean ± SD) 3.0 ± 1.9 2.8 ± 1.8
Positive Blood Culture Rate (%) 18.0% 29.0%
Febrile Neutropenia Rate (FN) (%) 18.0% 16.7%
Duration of FN (days) (mean ± SD) 5.1 ± 3.4 5.5 ± 4.980
PRIMARY CMV INFECTION IN CMV SERONEGATIVE RECIPIENTS OF
A STEM CELL PRODUCT FROM A SEROPOSITIVE DONOR (D1/R-): FRE-
QUENCY OF AND RISK FACTORS FOR TRANSMISSION
Sandhu, R.K., Smith, J., Kirby, K.A., Heimfeld, S., Corey, L.,
Boeckh, M. Fred Hutchinson Cancer Research Center, Seattle, WA.
Background: To evaluate if there is an effect of host and donor
factors in developing primary CMV infection in CMV D1/R- he-
matopoietic stem cell transplant (HCT) recipients. Method: Be-
tween 1/1996 and 12/2006, 392 D1/R- patients undergoing 1st
allogeneic HCT were evaluated retrospectively for host and donor
factors that may affect CMV transmission (recipient and donor age,
race, sex, and ABO type, stem cell source, stem cell types [CD14,
CD34, mononuclear cells] and overall number, underlying disease
risk, conditioning regimen, GVHD prophylaxis, acute GVHD,
TBI). Patients were evaluated for CMV antigenemia (AG) and/or
DNAemia until day 100 after HCT. Factors associated with
CMV transmission were evaluated by Cox regression models. All
patients received preemptive antiviral therapy for AG positivity.
Results:Of 392 D1/R- patients 383 (97.7%) were monitored reg-
ularly (AG: 345, AG and PCR: 29, PCR: 9) while and 9 (2.3%) were
not tested because of early death. By day 100, 57 patients (14.5%)
became antigenemia or PCR positive (50/345 [14.5%] by AG, 7/
29 [24.2%] by AG and PCR, and 0% by PCR only); 3 additional pa-
tients became positive at sites other than blood. CMV disease oc-
curred in 13 patients (3.3%) at a median of 111 days after HCT
(range 19–617 days). Of these, 6 cases occurred before day 100 (in-
cidence 1.5%) and 7 after day 100 (2.2%of patients alive at day 100).
Five patients with CMV disease after day 100 had CMV infection
diagnosed before day 100, resulting in an incidence of 8.8% among
those with early CMV infection. No statistically significant risk fac-
tors for CMV transmission via blood or marrow were identified.
However, ABO blood group B (hazard ratio 0.2, 95% CI 0.1–1.0,P 5 0.05, compared to all other groups) and the total number of
cells/kg transfused (HR 1.8, 95%0.9–3.8, P5 0.09, for values above
the 90th percentile) were borderline significant in multivariable
models. Conclusions: Transmision of CMV via marrow or stem
cells is uncommon. Although no significant risk factors were iden-
tified, the observed trends for cell counts and ABO blood groups
are interesting and suggest that the inoculum and perhaps genetic
factors may be important in determining transmission risk.
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PERFORMANCE STATUS, BUT NOT THE HEMATOPOIETIC CELL TRANS-
PLANTATION COMORBIDITY INDEX (HCT-CI), PREDICTS MORTALITY
AT A CANADIAN TRANSPLANT CENTRE
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Introduction: The hematopoietic cell transplantation-specific
comorbidity index (HCT-CI) was developed at a single centre in or-
der to predict outcomes for allogeneic transplant recipients who
have comorbidities. This index had a higher predictive power for
non-relapse mortality (NRM) and overall survival (OS) than other
tools such as the Charlson Comorbidity Index. The HCT-CI has,
to our knowledge, not been validated in unselected transplant recip-
ients at an institution outside the US. We evaluated whether the
HCT-CI predicts NRM and OS at a Canadian institution and
whether other readily available pre-transplant variables can predict
NRM andOS.Methods:Using a prospective cohort design, we an-
alyzed consecutive adult allogeneic HCT recipients between 01/
1990 and 12/2005. Comorbidity was scored according to the
HCT-CI. Kaplan-Meier survival curves were generated and hazard
ratios were calculated using the Cox model. Results: Of 187 pa-
tients, 64 had AML or MDS, 40 had CML, and 83 had other diag-
noses. Preparative regimens were myeloablative in 177 (95%).
Grafts were from related donors in 138 (74%). Stem cell source
was marrow in 134 (72%), peripheral blood in 51 (27%), and
both in 2 (1%). HCT-CI risk was low in 22 (12%), intermediate
in 50 (27%) and high in 104 (55%). Two year OS was 45% (95%
CI: 24%-64%), 55% (95% CI: 40%-68%), and 42% (95% CI:
32%-51%) in the low, intermediate and high risk HCT-CI groups
respectively. Two year NRM was 40% (95% CI: 21%-65%), 28%
(95%CI: 17%-43%), and 34% (95% CI: 25%-44%) in the low, in-
termediate, and high risk groups, respectively. In both univariate
andmultivariate analyses, theHCT-CI was not a significant predic-
tor of OS or NRM. In contrast, a KPS of\ 90% at HCT was
a strong predictor of post HCT OS and NRM. Conclusions:
The HCT-CI failed to predict NRM or OS at a Canadian trans-
plant institution. In contrast, KPS appeared to be a powerful inde-
pendent indicator of post-transplant survival.We suggest that large,
multicentre studies are required before the HCT-CI can be applied
in clinical practice.82
SEVERE HEMORRHAGIC CYSTITIS (HC) AFTER ALLOGENEIC HEMATO-
POEITIC STEM CELL TRANSPLANTATION (HSCT): INCIDENCE AND
RISK FACTORS
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HC is a major source of morbidity after HSCT. Severe HC often
results in prolonged hospitalizations, increased health care costs,
decreased quality of life and, rarely, death. Further elucidating
risk factors may lead to preventive strategies and early treatment.
We reviewed 208 cases of HC which occurred in 1353 allogeneic
HSCT recipients transplanted at the University of Minnesota
from 1995–2006. Severe HC was defined as urinary clots and blad-
der pain requiring bladder irrigation and/or sequelae such as ure-
thral and/or ureteral obstruction, renal failure and or the need for
surgical or chemical bladder cautery or coagulation. A total of 72
